Trial Profile
A single center, observational study analysing effect of baricitinib on ultrasound-detected synovial inflammation and bone damage in rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2021
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Bone disorders; Rheumatoid arthritis; Synovitis
- Focus Therapeutic Use
- 07 Sep 2021 New trial record
- 30 Jul 2021 Results published in the Medicine